方盛制药：中药创新药妇科止血消痛颗粒获批临床试验

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced that its subsidiary, Guangdong Fangsheng Runkang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a clinical trial of a traditional Chinese medicine product aimed at treating postpartum hemorrhage and pain [1]. Group 1 - The approved product is a traditional Chinese medicine formulation for the treatment of postpartum conditions characterized by prolonged lochia, abdominal pain, and other symptoms [1]. - The specific symptoms addressed by the product include excessive lochia, abdominal pain upon touch, dark purple blood clots, fatigue, and lower abdominal distension [1]. - The approval signifies a potential advancement in the company's product pipeline and may enhance its market position in the traditional Chinese medicine sector [1].